摘要
BACKGROUND: Patient-derived tumor organoid culture has emerged as a preclinical model that has the potential to predict individual drug response. However, the predictive accuracy of patient-derived tumor organoid culture models for responses to chemotherapy regimens in stage IV colorectal cancer remains unknown. @@@ OBJECTIVE: The purpose of this study was to evaluate the predictive accuracy of the patient-derived tumor organoid culture model for responses to chemotherapy regimens in stage IV colorectal cancer. @@@ DESIGN: A pilot study was performed to define the half-maximal inhibitory concentration of the response to chemotherapy regimens in the patient-derived tumor organoid culture model. Then, a blinded study was performed to evaluate the predictive accuracy of the patient-derived tumor organoid culture model for responses to chemotherapy regimens. @@@ SETTINGS: Cancer samples were collected from patients with stage IV colorectal cancer at Nanfang Hospital of Southern Medical University in China. @@@ PATIENTS: In the pilot study, 30 patients were enrolled, and 43 samples were collected. In the blinded study, 71 patients were enrolled, and 96 samples were collected. @@@ INTERVENTION: Patient-derived tumor organoid culture and chemotherapy regimens were tested. @@@ MAIN OUTCOME MEASURES: The predictive accuracy of the patient-derived tumor organoid model for responses to chemotherapy regimens was measured. @@@ RESULTS: The median (range) time of organoid culture and drug testing was 9 days (range, 7-14 d). In the pilot study, 30 samples (69.77% [30/43]) were successfully cultured. The half-maximal inhibitory concentration of the chemotherapy response was 10 mu mol/L according to clinical chemotherapy outcomes. In the blinded study, 77 samples (80.21% [77/96]) from 57 patients were successfully cultured. The sensitivity, specificity, and accuracy of the patient-derived tumor organoid model for predicting responses to chemotherapy regimens were 63.33%, 94.12%, and 79.69%. @@@ LIMITATIONS: This was a blinded study rather than a prospective randomized controlled study. @@@ CONCLUSIONS: The patient-derived tumor organoid culture model effectively predicts responses to existing chemotherapy regimens for individual patients.
学科与关键词
- Patient-Derived Tumor Organoids Can Predict the Progression-Free Survival of Patients With Stage IV Colorectal Cancer After SurgeryWang, Ting; Tang, Yuting; Pan, Wenjun; Yan, Botao; Hao, Yifan; Zeng, Yunli; Chen, Zexin; Lan, Jianqiang; Zhao, Shuhan; Deng, Chuxia; Zheng, Hang*; Yan, Jun*Diseases of the Colon and Rectum, 2023, 66(5): 733-743.被引 2
- Application of tumoroids derived from advanced colorectal cancer patients to predict individual response to chemotherapyYao, Lei; Zao, Xiao-Long; Pan, Xiao-Fei; Zhang, Hao-Gang; Wang, Fu-Jing; Qiao, Peng-Fei*JOURNAL OF CHEMOTHERAPY, 2023, 35(2): 104-116.被引 4
- Using patient-derived organoids to predict locally advanced or metastatic lung cancer tumor response: A real-world studyWang, Han-Min; Zhang, Chan-Yuan; Peng, Kai-Cheng; Chen, Ze-Xin; Su, Jun-Wei; Li, Yu-Fa; Li, Wen-Feng; Gao, Qing-Yun; Zhang, Shi-Ling; Chen, Yu-Qing; Zhou, Qing; Xu, Cong; Xu, Chong-Rui; Wang, Zhen; Su, Jian; Yan, Hong-Hong; Zhang, Xu-Chao; Chen, Hua-Jun*; Wu, Yi-Long*; Yang, Jin-Ji*CELL REPORTS MEDICINE, 2023, 4(2): 100911.被引 18
